Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24220
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rech, J. | - |
dc.contributor.author | Reinhardt, M. | - |
dc.contributor.author | Kavanaugh, A. | - |
dc.contributor.author | GEUSENS, Piet | - |
dc.contributor.author | Mpofu, S. | - |
dc.date.accessioned | 2017-08-11T14:35:55Z | - |
dc.date.available | 2017-08-11T14:35:55Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 15(S1), p. 141-141 (Art N° P138) | - |
dc.identifier.issn | 1610-0379 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24220 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 141 | - |
dc.identifier.issue | S1 | - |
dc.identifier.spage | 141 | - |
dc.identifier.volume | 15 | - |
local.format.pages | 1 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Rech, J.] Univ Erlangen Nurnberg, Dept Rheumatol & Immunol, Erlangen, Germany. [Reinhardt, M.] Novartis Pharma GmbH, Nurnberg, Germany. [Kavanaugh, A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Geusens, P.] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Mpofu, S.] Novartis Pharma AG, Basel, Switzerland. | - |
local.publisher.place | HOBOKEN | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
local.bibliographicCitation.artnr | P138 | - |
local.class | dsPublValOverrule/author_version_not_expected | - |
dc.identifier.isi | 000400154800356 | - |
item.fulltext | With Fulltext | - |
item.contributor | Rech, J. | - |
item.contributor | Reinhardt, M. | - |
item.contributor | Kavanaugh, A. | - |
item.contributor | GEUSENS, Piet | - |
item.contributor | Mpofu, S. | - |
item.fullcitation | Rech, J.; Reinhardt, M.; Kavanaugh, A.; GEUSENS, Piet & Mpofu, S. (2017) Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1. In: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 15(S1), p. 141-141 (Art N° P138). | - |
item.accessRights | Restricted Access | - |
crisitem.journal.issn | 1610-0379 | - |
crisitem.journal.eissn | 1610-0387 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
annrheumdis.pdf Restricted Access | Published version | 150.17 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.